Arch Venture Corp »

Rapport Therapeutics shares owned by Arch Venture Corp

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Arch Venture Corp from 13F filings

Historical chart of Arch Venture Corp investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Arch Venture Corp consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Arch Venture Corp

Quarter filed Position value Share count Share price at filing
2024-06-30 $87M 3.7M 23.26

More positions owned by Arch Venture Corp

Beam Therapeutics (BEAM)
Rapport Therapeutics (RAPP)
Erasca (ERAS)
Verve Therapeutics (VERV)
Gossamer Bio (GOSS)
Q32 Bio (QTTB)
Unity Biotechnology Com New (UBX)
Singular Genomics Systems Com New (OMIC)
Cero Therapeutics Holdings Class A Com (CERO)

View all positions for Arch Venture Corp

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Capital Research and Management Company - Division 3
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
Alliancebernstein
T. Rowe Price Associates
Perceptive Advisors
BlackRock
Citadel Advisors
Siren
Logos Global Management
Geode Capital Management
Woodline Partners

View all funds holding Rapport Therapeutics